Paper6843516
Radiation dose enhancement in tumors with iodine.
Santos Mello R and 4 others. Med Phys, 1983. Cited by 117 papers, by iCite.
Cite this record
ConductScience Library. Radiation dose enhancement in tumors with iodine. Papers, record 6843516. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6843516
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Contrast Media | Major topic |
| Diatrizoate | Major topic |
| Neoplasms | Major topic |
| Radiotherapy Dosage | Major topic |
| Animals | |
| Brain Neoplasms | |
| Chromosome Aberrations | |
| Female | |
| Glioma | |
| Humans | |
| Lymphocytes | |
| Mice | |
| Neoplasms, Experimental | |
| Rabbits |
Source PubMed
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 117 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41865179 | From Marker to Modulator: Lipiodol-Mediated Dose Enhancement in Liver Tumor Radiotherapy. | Cardiovasc Intervent Radiol | 2026 | https://conductscience.org/library/papers/41865179 | PubMed |
| 41692835 | Lipiodol-Mediated Dose Enhancement in Radiation Therapy: A Phantom and In Vitro Study in Hepatocellular Carcinoma. | Cardiovasc Intervent Radiol | 2026 | https://conductscience.org/library/papers/41692835 | PubMed |
| 39611766 | Enhancing targeted doses: Low-energy photon lipiodol-enhanced radiotherapy (LEPERT) for liver cancer patients. | J Appl Clin Med Phys | 2025 | https://conductscience.org/library/papers/39611766 | PubMed |
| 39014282 | Enhanced radio-photodynamic therapy potential of advanced gold-based nanoclusters for breast cancer treatment. | Radiol Phys Technol | 2024 | https://conductscience.org/library/papers/39014282 | PubMed |
| 38893315 | Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment. | Molecules | 2024 | https://conductscience.org/library/papers/38893315 | PubMed |
| 37781236 | Dual enhancement in the radiosensitivity of prostate cancer through nanoparticles and chemotherapeutics. | Cancer Nanotechnol | 2023 | https://conductscience.org/library/papers/37781236 | PubMed |
| 37686211 | Study of Nuclear Reactions in Therapy of Tumors with Proton Beams. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37686211 | PubMed |
| 37555747 | Prospects of nanoparticle-based radioenhancement for radiotherapy. | Mater Horiz | 2023 | https://conductscience.org/library/papers/37555747 | PubMed |
| 36816996 | Synthesis and characterization of actively HER-2 Targeted Fe3O4@Au nanoparticles for molecular radiosensitization of breast cancer. | Bioimpacts | 2023 | https://conductscience.org/library/papers/36816996 | PubMed |
| 36559288 | Repurposing Antimalarial Pyronaridine as a DNA Repair Inhibitor to Exploit the Full Potential of Gold-Nanoparticle-Mediated Radiation Response. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559288 | PubMed |
| 35835744 | Breaking photoswitch activation depth limit using ionising radiation stimuli adapted to clinical application. | Nat Commun | 2022 | https://conductscience.org/library/papers/35835744 | PubMed |
| 35335886 | Iodine Nanoparticles (Niodx™) for Radiotherapy Enhancement of Glioblastoma and Other Cancers: An NCI Nanotechnology Characterization Laboratory Study. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35335886 | PubMed |
| 34575482 | Gold-Protein Composite Nanoparticles for Enhanced X-ray Interactions: A Potential Formulation for Triggered Release. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34575482 | PubMed |
| 33101867 | Radiation Dose-Enhancement Is a Potent Radiotherapeutic Effect of Rare-Earth Composite Nanoscintillators in Preclinical Models of Glioblastoma. | Adv Sci (Weinh) | 2020 | https://conductscience.org/library/papers/33101867 | PubMed |
| 32973267 | Iodine nanoparticle radiotherapy of human breast cancer growing in the brains of athymic mice. | Sci Rep | 2020 | https://conductscience.org/library/papers/32973267 | PubMed |
| 30872755 | Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy. | Sci Rep | 2019 | https://conductscience.org/library/papers/30872755 | PubMed |
| 30218059 | Small, Long Blood Half-Life Iodine Nanoparticle for Vascular and Tumor Imaging. | Sci Rep | 2018 | https://conductscience.org/library/papers/30218059 | PubMed |
| 28287916 | The Effect of Contrast Material on Radiation Dose at CT: Part II. A Systematic Evaluation across 58 Patient Models. | Radiology | 2017 | https://conductscience.org/library/papers/28287916 | PubMed |
| 27446499 | Standards and Methodologies for Characterizing Radiobiological Impact of High-Z Nanoparticles. | Theranostics | 2016 | https://conductscience.org/library/papers/27446499 | PubMed |
| 27255899 | Synergistic Effects of Gold Nanocages in Hyperthermia and Radiotherapy Treatment. | Nanoscale Res Lett | 2016 | https://conductscience.org/library/papers/27255899 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6843516
GET https://conductscience.org/api/papers/v1/6843516/cited_by?page=2